tradingkey.logo

Smith & Nephew PLC

SNN
查看详细走势图
32.845USD
+0.145+0.44%
收盘 12/19, 16:00美东报价延迟15分钟
14.39B总市值
29.22市盈率 TTM

Smith & Nephew PLC

32.845
+0.145+0.44%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.44%

5天

+0.66%

1月

+2.67%

6月

+13.93%

今年开始到现在

+33.62%

1年

+33.19%

查看详细走势图

TradingKey Smith & Nephew PLC股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Smith & Nephew PLC当前公司基本面数据相对健康,增长潜力很大。当前估值低估,在医疗设备与耗材行业排名92/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价34.16。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Smith & Nephew PLC评分

相关信息

行业排名
92 / 208
全市场排名
217 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 4 位分析师
买入
评级
34.157
目标均价
+1.99%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Smith & Nephew PLC亮点

亮点风险
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
利润高增长
公司净利润处于行业前列,最新年度总收入5.81B美元
高分红
公司属于高分红公司,最新股息支付率79.37%
稳定分红
公司5年内连续分红,最新股息支付率79.37%
估值低估
公司最新PE估值29.20,处于3年历史低位
机构减仓
最新机构持股32.77M股,环比减少26.97%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值14.85K

Smith & Nephew PLC新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Smith & Nephew PLC简介

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
公司代码SNN
公司Smith & Nephew PLC
CEONath (Deepak S)
网址https://www.smith-nephew.com/

常见问题

Smith & Nephew PLC(SNN)的当前股价是多少?

Smith & Nephew PLC(SNN)的当前股价是 32.845。

Smith & Nephew PLC的股票代码是什么?

Smith & Nephew PLC的股票代码是SNN。

Smith & Nephew PLC股票的52周最高点是多少?

Smith & Nephew PLC股票的52周最高点是38.790。

Smith & Nephew PLC股票的52周最低点是多少?

Smith & Nephew PLC股票的52周最低点是23.690。

Smith & Nephew PLC的市值是多少?

Smith & Nephew PLC的市值是14.39B。

Smith & Nephew PLC的净利润是多少?

Smith & Nephew PLC的净利润为412.00M。

现在Smith & Nephew PLC(SNN)的股票是买入、持有还是卖出?

根据分析师评级,Smith & Nephew PLC(SNN)的总体评级为买入,目标价格为34.157。

Smith & Nephew PLC(SNN)股票的每股收益(EPS TTM)是多少

Smith & Nephew PLC(SNN)股票的每股收益(EPS TTM)是1.124。
KeyAI